The complement receptor C3AR constitutes a novel therapeutic target in NPM1-mutated AML

  1. von Palffy, S.
  2. Thorsson, H.
  3. Penã-Martínez, P.
  4. Puente-Moncada, N.
  5. Sandén, C.
  6. Blom, A.M.
  7. Henningsson, R.
  8. Juliusson, G.
  9. King, B.
  10. Landberg, N.
  11. Lazarevic, V.
  12. Orsmark-Pietras, C.
  13. Rissler, M.
  14. Rissler, V.
  15. Ågerstam, H.
  16. Järås, M.
  17. Lilljebjörn, H.
  18. Fioretos, T.
Journal:
Blood Advances

ISSN: 2473-9537 2473-9529

Year of publication: 2023

Volume: 7

Issue: 7

Pages: 1204-1218

Type: Article

DOI: 10.1182/BLOODADVANCES.2022007682 GOOGLE SCHOLAR lock_openOpen access editor